The acquisition of MRI scans has been extensively described previously [24 (link)]. During the period of 2005 to 2017, the following scanners have been used: Discovery MR750 and Signa HDXT (both GE Medical Systems, USA), Ingenuity TF PET/MR (Philips Medical Systems, The Netherlands), Titan (Toshiba Medical Systems, Japan), and Magnetom Impact and Sonata (Siemens Healthcare, Germany). The MRI protocol included 3D T1-weighted, T2-weighted, fluid-attenuated inversion recovery (FLAIR), gradient-echo T2*, and/or susceptibility-weighted imaging sequences. The scans were visually assessed by a neuroradiologist on three different image planes. Parietal atrophy was rated using the posterior cortical atrophy (PCA) scale [46 (link)], medial temporal atrophy using the medial temporal lobe atrophy (MTA) scale [47 (link)], and the extent of white matter hyperintensities according to the Fazekas scale [48 (link)]. MTA and PCA scores were scored separately for right and left and averaged thereafter. In addition, the scans were assessed for the existence of lacunes and microbleeds.
Free full text: Click here